Teva Wins Bidding For NuPathe And Its Migraine Patch, Topping Endo
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will be responsible for launching the Zecuity migraine patch after acquiring NuPathe for $144 million upfront. Teva’s $3.65 per share offer for NuPathe trumps Endo’s $2.85 per share, or $105 million, offer.